Kathryn E. Falberg, Director at Arcus Biosciences, Inc. (RCUS), bought 47,106 shares at $15.00 ($450K) on 2018-03-19, disclosed to the SEC on 2018-03-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 17,106 | $0 | 0.0% |
| 2 | $15.00 | 30,000 | $450K | 100.0% |
| Total | $9.55 avg | 47,106 | $450K | 100% |
| Filing → |
| TTD | SELL | 2024-03-12 | $16.9M | — | Filing → |
| NUVB | BUY | 2022-12-05 | $789K | — | Filing → |
| TTD | SELL | 2021-11-23 | $32.5M | — | Filing → |